Advocacy

Member Spotlight: Relentless in Care: The Journey of TJ Chao, PA-C

For more than two decades, TJ Chao, PA-C, has been at the forefront of some of the most significant advances in dermatology.

SDPA Statement on FDA Withdrawing Proposed Ban of Minors Using Sunlamps

The Society of Dermatology Physician Associates (SDPA) expresses its disappointment in the U.S. Food and Drug Administration’s (FDA) decision to withdraw its proposal to ban minors from using sunlamps.  

SDPA Statement on Topical Steroids

The Society of Dermatology Physician Assistants (SDPA) recognizes emerging evidence on potential adverse effects associated with prolonged topical corticosteroid use in managing chronic inflammatory dermatoses. These findings highlight the need for vigilant treatment planning to mitigate long-term risks. To prioritize patient safety and optimize outcomes, the SDPA advocates for routine assessment of cumulative steroid exposure as a cornerstone of patient care.

From the Hill: What the One Big Beautiful Bill Act Means for Dermatology PAs

Washington recently passed the wide-ranging One Big Beautiful Bill Act, a sweeping legislative package that touches everything from energy to tax reform.

Apremilast and IRA

The IRA’s drug price negotiations aim to lower costs but risk limiting patient access, treatment options, and future innovation. The SDPA urges policymakers to balance affordability with maintaining a broad range of therapies essential for individualized patient care.

Pharmacy Benefit Reform - New York S.1267-A

Pharmacy Benefit Reform Fails in 118th Congress New York S.1267-A Sets Precedent for States Moving Forward